Last edition
News about "Mirum Pharmaceuticals "
Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome
Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.
Mirum Pharmaceuticals | 07/02/2026 | By News Bureau | 118
XOMA Royalty and Takeda Amend Mezagitamab Agreement in Royalty Sharing Deal
XOMA Royalty and Takeda have completed a royalty sharing transaction amending their mezagitamab (TAK-079) agreement, with Takeda regaining a majority interest while XOMA Royalty gains milestone and royalty payments linked to nine development-stage assets in Takeda’s externalised portfolio.
Mirum Pharmaceuticals | 31/12/2025 | By News Bureau | 144
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy